MICHAEL R MIGDEN to Antineoplastic Agents, Immunological
This is a "connection" page, showing publications MICHAEL R MIGDEN has written about Antineoplastic Agents, Immunological.
Connection Strength
1.245
-
CASE (CemiplimAb-rwlc Survivorship and Epidemiology) study in advanced cutaneous squamous cell carcinoma. Future Oncol. 2020 Feb; 16(4):11-19.
Score: 0.354
-
Cemiplimab in locally advanced cutaneous squamous cell carcinoma: results from an open-label, phase 2, single-arm trial. Lancet Oncol. 2020 02; 21(2):294-305.
Score: 0.354
-
Emerging Nonsurgical Therapies for Locally Advanced and Metastatic Nonmelanoma Skin Cancer. Dermatol Surg. 2019 01; 45(1):1-16.
Score: 0.330
-
Current and emerging intralesional immunotherapies in cutaneous oncology. J Am Acad Dermatol. 2024 Nov; 91(5):910-921.
Score: 0.121
-
Cemiplimab-rwlc as first and only treatment for advanced cutaneous squamous cell carcinoma. Expert Rev Clin Pharmacol. 2019 Oct; 12(10):947-951.
Score: 0.087